Satyendra K. Prasad

Dr. Satyendra K. Prasad

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
SSSaurabh K. Sinha
Saurabh K. Sinha
SPSatyendra K. Prasad
Satyendra K. Prasad
MIMd Ataul Islam
Md Ataul Islam
Shailendra Shivaji GuravShailendra Shivaji Gurav
Shailendra Shivaji Gurav
RPRajesh Bhimgonda Patil
Rajesh Bhimgonda Patil
ASAnshul Shakya
Anshul Shakya
At present, the world is facing a pandemic named as COVID-19, caused by SARS-CoV-2. Traditional Chinese medicine has recommended the use of liquorice (Glycyrrhiza species) in the treatment of infections caused by SARS-CoV-2. Therefore, the present investigation was carried out to identify the active molecule from the liquorice against different protein targets of COVID-19 using an in-silico approach. The molecular docking simulation study of 20 compounds along with two standard antiviral drugs (Lopinavir and Rivabirin) was carried out with the help of Autodock vina software using two protein targets from COVID-19 i.e. spike glycoprotein (PDB ID: 6VSB) and Non-structural Protein-15 (Nsp15) endoribonuclease (PDB ID: 6W01). From the observed binding energy and the binding interactions, glyasperin A showed high affinity towards Nsp15 endoribonuclease with uridine specificity, while glycyrrhizic acid was found to be best suited for the binding pocket of spike glycoprotein and also prohibited the entry of the virus into the host cell. Further, the dynamic behavior of the best-docked molecules inside the spike glycoprotein and Nsp15 endoribonuclease were explored through all-atoms molecular dynamics (MD) simulation study. Several parameters from the MD simulation have substantiated the stability of protein-ligand stability. The binding free energy of both glyasperin A and glycyrrhizic acid was calculated from the entire MD simulation trajectory through the MM-PBSA approach and found to high binding affinity towards the respective protein receptor cavity. Thus, glyasperin A and glycyrrhizic acid could be considered as the best molecule from liquorice, which could find useful against COVID-19. Communicated by Ramaswamy H. Sarma

22 June 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
RCRupesh V Chikhale
Rupesh V Chikhale
Shailendra Shivaji GuravShailendra Shivaji Gurav
Shailendra Shivaji Gurav
RPRajesh Bhimgonda Patil
Rajesh Bhimgonda Patil
SSSaurabh K. Sinha
Saurabh K. Sinha
SPSatyendra K. Prasad
Satyendra K. Prasad
RPRupali S. Prasad
Rupali S. Prasad
COVID-19 has ravaged the world and is the greatest of pandemics in modern human history, in the absence of treatment or vaccine, the mortality and morbidity rates are very high. The present investigation identifies potential leads from the plant Withania somnifera (Indian ginseng), a well-known antiviral, immunomodulatory, anti-inflammatory and a potent antioxidant plant, using molecular docking and dynamics studies. Two different protein targets of SARS-CoV-2 namely NSP15 endoribonuclease and receptor binding domain of prefusion spike protein from SARS-CoV-2 were targeted. Molecular docking studies suggested Withanoside X and Quercetin glucoside from W. somnifera have favorable interactions at the binding site of selected proteins, that is, 6W01 and 6M0J. The top-ranked phytochemicals from docking studies, subjected to 100 ns molecular dynamics (MD) suggested Withanoside X with the highest binding free energy (ΔGbind = −89.42 kcal/mol) as the most promising inhibitor. During MD studies, the molecule optimizes its conformation for better fitting with the receptor active site justifying the high binding affinity. Based on proven therapeutic, that is, immunomodulatory, antioxidant and anti-inflammatory roles and plausible potential against n-CoV-2 proteins, Indian ginseng could be one of the alternatives as an antiviral agent in the treatment of COVID 19. Communicated by Ramaswamy H. Sarma

1 February 2017 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
KPKomal M. Parmar
Komal M. Parmar
PIPrakash R. Itankar
Prakash R. Itankar
AJApurva Joshi
Apurva Joshi
SPSatyendra K. Prasad
Satyendra K. Prasad

17 January 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
DSDivya Sharma
Divya Sharma
SSSupriya Sharma
Supriya Sharma
NANATASHA AKOJWAR
NATASHA AKOJWAR
ADAyusha Omprakash Dondulkar
Ayusha Omprakash Dondulkar
NYNikhil Yadavrao Yenorkar
Nikhil Yadavrao Yenorkar
MDMahaveer Dhobi
Mahaveer Dhobi
Herpes simplex virus (HSV) infection, the most prevalent viral infection that typically lasts for a lifetime, is associated with frequent outbreaks of oral and genital lesions. Oral herpes infection is mainly associated with HSV-1 through oral contact, while genital herpes originates due to HSV-2 and is categorized under sexually transmitted diseases. Immunocompromised patients and children are more prone to HSV infection. Over the years, various attempts have been made to find potential targets for the prevention of HSV infection. Despite the global distress caused by HSV infections, there are no licensed prophylactic and therapeutic vaccines available on the market against HSV. Nevertheless, there are numerous promising candidates in the pre-clinical and clinical stages of study. The present review gives an overview of two herpes viruses, their history, and life cycle, and different treatments adopted presently against HSV infections and their associated limitations. Majorly, the review covers the recent investigations being carried out globally regarding various vaccine strategies against oral and genital herpes virus infections, together with the recent and advanced nanotechnological approaches for vaccine development. Consequently, it gives an insight to researchers as well as people from the health sector about the challenges and upcoming solutions associated with treatment and vaccine development against HSV infections.

1 January 2021 in Informatics in Medicine Unlocked
Verified
Journal Article
Open access
RPRajesh Patil
Rajesh Patil
RCRupesh V Chikhale
Rupesh V Chikhale
PKPukar Khanal
Pukar Khanal
NGNilambari Gurav
Nilambari Gurav
Muniappan AyyanarMuniappan Ayyanar
Muniappan Ayyanar
Shailendra Shivaji GuravShailendra Shivaji Gurav
Shailendra Shivaji Gurav
Bioflavonoids are the largest group of plant-derived polyphenolic compounds with diverse biological potential and have also been proven efficacious in the treatment of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The present investigation validates molecular docking, simulation, and MM-PBSA studies of fifteen bioactive bioflavonoids derived from plants as a plausible potential antiviral in the treatment of COVID-19. Molecular docking studies for 15 flavonoids on the three SARS CoV-2 proteins, non-structural protein-15 Endoribonuclease (NSP15), the receptor-binding domain of spike protein (RBD of S protein), and main protease (Mpro/3CLpro) were performed and selected protein-ligand complexes were subjected to Molecular Dynamics simulations. The molecular dynamics trajectories were subjected to free energy calculation by the MM-PBSA method. All flavonoids were further assessed for their effectiveness as adjuvant therapy by network pharmacology analysis on the target proteins. The network pharmacology analysis suggests the involvement of selected bioflavonoids in the modulation of multiple signaling pathways like p53, FoxO, MAPK, Wnt, Rap1, TNF, adipocytokine, and leukocyte transendothelial migration which plays a significant role in immunomodulation, minimizing the oxidative stress and inflammation. Molecular docking and molecular dynamics simulation studies illustrated the potential of glycyrrhizic acid, amentoflavone, and mulberroside in inhibiting key SARS-CoV-2 proteins and these results could be exploited further in designing future ligands from natural sources.

1 April 2020 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JHJayshri R. Hirudkar
Jayshri R. Hirudkar
KPKomal M. Parmar
Komal M. Parmar
RPRupali S. Prasad
Rupali S. Prasad
SSSaurabh K. Sinha
Saurabh K. Sinha
ALAmarsinh D. Lomte
Amarsinh D. Lomte
SPSatyendra K. Prasad
Satyendra K. Prasad